King'S College London is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
Location
London, United Kingdom
Type
Public Research University
Website
[kcl.ac.uk](https://www.kcl.ac.uk)
Notable Schools
Institute of Psychiatry, Psychology & Neuroscience (IoPPN)
King's College London is a public research university located in London, England. Founded in 1829, it is one of the world's leading universities and home to the Institute of Psychiatry, Psychology & Neuroscience (IoPPN) - one of the largest neuroscience research centers in Europe.
The IoPPN at King's is a global leader in brain research:
- Over 1,200 researchers studying brain disorders
- £100M+ annual research budget
- State-of-the-art neuroimaging facilities (MR-PET, 7T MRI)
- Close partnership with South London and Maudsley NHS Foundation Trust
King's leads major AD research programs:
- UK Dementia Research Institute at King's: £150M flagship institute
- Neuroimaging biomarkers for early detection
- Tau and amyloid mechanisms
- Clinical trials for disease-modifying therapies
The IoPPN has major PD research programs:
- Alpha-synuclein propagation mechanisms
- LRRK2 biology and therapeutics
- Deep brain stimulation research
- Non-motor symptoms of PD
King's is a world leader in:
- Schizophrenia genetics and neuroscience
- Depression and anxiety disorders
- Bipolar disorder research
- Neurodevelopmental disorders
- Professor Sir John O'Brien: Leading authority on Alzheimer's disease biomarkers
- Professor Oliver Howes: Schizophrenia and psychosis research
- Professor Steven Williams: Neurodegeneration mechanisms
- Dr. Rita Sattler: FTD and TDP-43 research
| Disease |
Research Focus |
| Alzheimer's Disease |
Biomarkers, tau, clinical trials |
| Parkinson's Disease |
Alpha-synuclein, LRRK2, DBS |
| Frontotemporal Dementia |
TDP-43, FUS, genetics |
| Schizophrenia |
Neuroimaging, genetics |
- Maurice Wohl Clinical Neuroscience Institute: £45M state-of-the-art research facility
- NIHR Maudsley Biomedical Research Centre: Clinical translation hub
- King's College Hospital: Leading NHS neuroscience center
- Broad Institute (Harvard/MIT)
- National Institute of Mental Health (NIMH)
- European Alzheimer's Disease Consortium
King's College London was founded in 1829 by King George IV and the Duke of Wellington, making it one of the oldest universities in England. The university's Institute of Psychiatry was established in 1948 and has grown to become the Institute of Psychiatry, Psychology & Neuroscience (IoPPN), one of the world's leading centers for brain research. King's has played a pivotal role in advancing our understanding of neurodegenerative diseases, particularly Alzheimer's and Parkinson's disease.
King's College London offers extensive training opportunities in neurodegeneration:
- PhD Programs: MRC DTP in Neuroscience, Wellcome Trust PhD in Mental Health Research
- Clinical Training: Neurology residency, old age psychiatry fellowship, movement disorders fellowship
- Masters Programs: MSc in Neuroscience, MSc in Clinical Neuroscience, MSc in Dementia
- Postdoctoral Programs: King's Postdoctoral Fellowship, IoPPN Research Fellowships
King's researchers have made breakthrough discoveries in neurodegeneration:
- Alpha-Synuclein Research: Pioneering studies on alpha-synuclein aggregation mechanisms in Parkinson's disease
- Biomarker Development: Development of novel CSF and blood biomarkers for Alzheimer's and Parkinson's
- Genetics: Identification of new risk genes for Alzheimer's disease through genome-wide studies
- Clinical Trials: Leadership in landmark clinical trials for new Alzheimer's and Parkinson's therapeutics
King's College London has outlined ambitious plans for neurodegeneration research:
- AI for Neuroscience: New AI and machine learning center focused on neurological disease
- Cell Therapy Initiative: Development of cell replacement therapies for Parkinson's disease
- Global Health: Expanded partnerships with research centers in India and Africa
- Drug Discovery: New drug discovery platform targeting protein misfolding in neurodegeneration
The IoPPN at King's remains at the forefront of translating basic neuroscience discoveries into clinical applications for patients with neurodegenerative diseases.
The study of King'S College London has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
- King's College London Annual Research Report 2025
- IoPPN Strategic Plan 2025-2030
- UK DRI at King's Annual Scientific Meeting Proceedings
- Nature Neuroscience: King's Research Highlights